Compare 10X Genomics Inc (TXG) vs Exxon Mobil Corporation (XOM) Price & Performance

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.

Exxon Mobil (XOM) trades at $164.06, down 0.26% on the day, with a bullish technical signal and strong support at $163. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains solid profitability with a 9.07% net margin. Recent news highlights potential expansion into Venezuela's oil fields and ongoing growth in Guyana and Permian Basin assets. Cash flow from operations remains robust at $52.0 billion in 2025, though net cash flow was negative due to high capital expenditures.

XOM offers a stable dividend and growth potential from strategic investments, but faces risks from volatile oil prices and geopolitical exposure. Analyst consensus is a 'Hold' with a $169.45 price target, indicating modest upside. Revenue declines from 2022-2025 pose a concern, but projected 2026 growth to $361.1 billion may reverse the trend. The stock's valuation ratios, including a P/E of 21.69, are reasonable for the energy sector.